Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert

The efficacy and safety of ectoine-containing eye drops in patients with allergic conjunctivitis

Search Title by author or title

Session Details

Session Title: Ocular Surface & Quality of Vision

Session Date/Time: Monday 24/09/2018 | 14:00-16:00

Paper Time: 14:12

Venue: Room A3, Podium 1

First Author: : E.Mrukwa-Kominek POLAND

Co Author(s): :    W. Lubon   J. Janiszewska-Salamon   R. Kinasz              

Abstract Details


The aim of the study was to evaluate the efficacy of ectoine-containing eye drops in patients with allergic conjunctivitis.


Department of Ophthalmology, Silesian University of Medicine, Katowice, Poland


We evaluated the efficacy and tolerance of ectoine eye drops as well as the impact thereof on the quality of life in patients with allergic conjunctivitis. The study group comprised 30 patients (60 eyes) diagnosed with allergic conjunctivitis and treated with ectoine-containing eye drops for 14 to 21 days. At each follow-up time slit-lamp examination was performed, therapeutic efficiency and adverse effects were carefully monitored. In order to determine vision-related quality of life, the participants were asked to complete the McMonnies Questionaire, the OSDI score was also calculated.


Ocular symptoms of allergic conjunctivitis were significantly alleviated following a 21 day course of ectoine eye drops. OSDI was reduced by 14.4% compared to pre-treatment results (Wilcoxon test: p=0.0001 ). Conjunctival injection decreased by 1-2 points on a 5 point McMonnies scale. Blepharedema, itching and excesive tearing were also significantly reduced, respectively in 85, 76 and 90% of eyes. The statistical analysis did not reveal significant correlation between IOP and UCVA both before and after ectoin application (p>0.05)


Treatment tolerance was good with very few adverse effects and significant improvement of vision-related quality of life.

Financial Disclosure:


Back to previous